

DANPROST SEPTEMBER 2021

The COVID-19 situation has taken its toll on all of us and as a result it has been a while since we've had the opportunity to gather as a community to discuss the current status of prostate cancer treatment.

Luckily, despite the COVID-19 situation the evolution of prostate cancer treatment is under rapid development.

Therefore, it is with great anticipation and joy that the steering committee of the Danish Prostate Cancer symposium (DANPROST) would like to invite you to a two-day symposium to discuss the most recent advances in prostate cancer treatment – from curative therapy to castration-resistant prostate cancer.

The event will take place in Copenhagen at Clarion Hotel, September 24-25, 2021.

Our program can be found below.

On behalf of The DANPROST Steering Committee

Martin Andreas Røder, Professor, Department of Urology and Copenhagen Prostate Cancer Center, Rigshospitalet.

Thomas Helgstrand, MD, PhD, Department of Urology and Copenhagen Prostate Cancer Center, Rigshospitalet.

Per Kongsted, MD, PhD, Department of Oncology, Herlev Hospital.

Klaus Brasso, Professor, Chief Physician, Department of Urology and Copenhagen Prostate Cancer Center, Rigshospitalet.



[Register here](#)

Sponsored and organized by

Janssen Oncology

PHARMACEUTICAL COMPANIES OF *Johnson & Johnson*

AGENDA

FRIDAY SEPTEMBER 24, 2021

12.00-12.45	Arrival, check-in and pick-up lunch	
12.45-13.00	Welcome	Steering Committee
13.00-13.45	Biomarkers in patient failing primary curative therapy, PSA or new markers?	Jack Schalken
13.45-14.00	Break	
14.00-14.45	The role of modern imaging studies in men with PSA recurrence following curative therapy	Stefano Fanti
14.45-15.30	Biochemical recurrence following radical prostatectomy, the role of preoperative risk factors and salvage radiation	Chris Parker
15.30-16.00	Coffee break	
16.00-16.45	The role of surgical salvage procedures, salvage lymph-adenectomy and salvage prostatectomy in men with recurrence following radiation therapy	Markus Graefen
16.45-17.00	Break	
17.00-18.00	Is salvage procedures needed in all men with biochemical recurrence following curatively intend treatment, the natural history of an increasing PSA and patient selection for salvage procedures	Ola Bratt
18.00-19.00	Own time	
19.00-21.00	Dinner	

SATURDAY SEPTEMBER 25, 2021

07.00-08.15	Breakfast	
08.15-09.00	"The role of adding chemotherapy to standard endocrine therapy in men with PSA recurrence"	Andreas Josefsson
09.00-09.45	The role of primary stereotatic radiation in men with newly diagnosed oligometastatic prostate cancer	Piet Ost
09.45-10.00	Coffee break	
10.00-10.45	The role of surgical management of oligo metastatic lesions.	Marcus Graefen
10.45-11.30	The role of stereotatic radiation in men with oligometastatic failure following curative therapy	Piet Ost
11.30-12.15	Lunch	
12.15-13.00	Timing of endocrine therapy following failure of primary curative therapy	Jan-Erik Damber
13.00-13.45	Genomic sequencing of metastatic prostate cancer. When, how and what to look for?	Henrik Grönberg
13.45-14.15	Concluding remarks and farewell	Steering Committee

Janssen-Cilag A/S cares about your privacy and wants you to be familiar with how we collect, use, and disclose information. To manage our professional relationship with you, we will use your information in accordance with our Privacy Policy <https://www.janssen.com/denmark/privatlivspolitik>. The event is/will be reported to ENLI (the Danish Ethical Board of the Medical Industry) before the event is held. The organizers believe that the arrangement is in accordance with the rules in this area, although that the event is not approved in advance by ENLI.

Sponsored and organized by

